Italia markets closed

Dow Jones
39.806,77
-196,82(-0,49%)
Nasdaq
16.794,88
+108,91(+0,65%)
Nikkei 225
39.069,68
+282,30(+0,73%)
EUR/USD
1,0861
-0,0011(-0,10%)
Bitcoin EUR
63.781,01
+2.795,57(+4,58%)
CMC Crypto 200
1.468,53
+114,11(+8,43%)

NVCR Jan 2026 25.000 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

12,20

0,00

(0,00%)

In data: 12:46PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in